Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AriBio Co., Ltd.

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Milestone Achievement to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
From AriBio Co., Ltd.
Via Business Wire
AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease
From AriBio Co., Ltd.
Via Business Wire
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
From AriBio Co., Ltd.
Via Business Wire
AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD
From AriBio Co., Ltd.
Via Business Wire
MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer’s Disease Registration Trial
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)
From AriBio Co., Ltd.
Via Business Wire
First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer’s Disease
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA
From AriBio Co., Ltd.
Via Business Wire
The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study
From AriBio Co., Ltd.
Via Business Wire
AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients
From AriBio Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.